Rayner acquires Omidria to expand surgical offering in USA and Europe

Rayner Surgical Group (‘Rayner’) and Omeros Corporation (‘Omeros’) are delighted to announce the transfer of Omeros’ ophthalmology assets, including OmidriaTM, to Rayner. This will enable the creation of a significant commercial, regulatory and marketing infrastructure in the US, with a broad range of products, including intraocular lenses (IOLs), for cataract surgeons. OmidriaTM has excellent and substantial clinical data supporting the maintenance …

Evoq Technologies LLC Announces Launch of First Smartphone-Based Product for Retinal Health Testing

Evoq Technologies is excited to announce the FDA registration of the first in its family of products based on its proprietary smartphone-based biosensor technology. Dubbed the ‘SmartERG’ Platform, it’s built to test the eye’s retinal health in unique ways. About the science: By flashing a controlled light at the eye, we can evoke an electrical-physiological response from the retina that …

Researchers Find that Prozac Blocks the Inflammation that Leads to Dry AMD

Researchers at the University of Virginia who were looking at the potential of repurposing non-ophthalmic approved drugs for the treatment of dry age-related macular degeneration (AMD) found that the antidepressant fluoxetine, commonly known as Prozac, blocks the inflammation that can lead to the blinding condition. An experimental drug called CY-09 has been found to block that inflammatory process by binding …

Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastic

Santen unveiled plans to launch the first bio-based plastic eye drop bottle in the Europe, Middle East and Africa (EMEA) region. The plastic element of the bottles is made from a sugar cane-derived material called “I’m green Polyethylene.” This uses natural resources while maintaining the structural integrity of traditional plastic thus ensuring the medication is stable and reaches the patient in perfect condition, according to Santen. The bottles were introduced in Japan in June, 2021, followed by EMEA in early 2023. Santen’s efforts toward a …

Alcon Acquires Ivantis for $475 Million, Plus Potential Milestone Payments

Alcon has bolstered its glaucoma surgical device portfolio with the acquisition of Ivantis and its Hydrus Microstent. Alcon, a Switzerland-registered company with US headquarters in Texas, announced Nov. 8 that it would pay $475 million up front, plus potential milestone payments, for Ivantis, of Irvine, California. The transaction is expected to close in Q1-2022.

Sanofi to Invest up to $60 Million in Gyroscope Therapeutics

UK-based Gyroscope Therapeutics announced Nov. 8 that France’s Sanofi had committed to invest up to $60 million in equity in Gyroscope. Sanofi will invest $40 million initially, at a premium to Gyroscope’s prior Series C financing, and the remaining $20 million will be contingent on a future qualifying investment round and subject to certain closing conditions. Under the agreement, a …

EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeutics

EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’s pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which …

Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDA

In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product. Eyenovia will provide additional information to the FDA, as requested in the CRL, as soon as possible, including information necessary to meet additional requirements under Genus Medical …